Marigold Therapeutics

Marigold Therapeutics is a preclinical-stage biotechnology company focused on developing novel small molecule therapies for neurodegenerative diseases. The company's primary focus is on Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), conditions characterized by the pathological aggregation of the TDP-43 protein. Marigold utilizes a proprietary drug discovery platform to identify compounds that can restore normal RNA metabolism and prevent protein misfolding. As a spin-out from the University of Oxford, the company leverages deep expertise in RNA biology and proteinopathy. Their lead programs aim to address the root causes of neurodegeneration rather than providing symptomatic relief. The company is backed by prominent life science investors and maintains strong ties to academic research centers in the United Kingdom.